Alvotech faces compounding headwinds — revenue declined more than 20% over the past year, free cash flow is negative, and the most recent earnings report missed estimates by nearly 29% — all while the stock trades in a confirmed long-term downtrend; absent a clear catalyst for operational stabilization, the risk/reward is unfavorable.
Thesis pillars
- Revenue Decline Value Trap↑Improving
- Negative Free Cash Flow→Stable
- Confirmed Price Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Alvotech (ALVO) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $4.94: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration,... Read more
Sell if holding. Engine safety override at $4.94: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Alvotech
Latest news
- NEWS What forecasting risk Alvotech (ALVO)? (-6.25%) 2026-04-29 - Chart Patterns - Newser — Newser negative
- NEWS What forecasting risk Alvotech (ALVO)? (-6.25%) 2026-04-29 - Momentum Signals - Newser — Newser negative
- NEWS Alvotech (ALVO) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Alvo Minerals Sets May 2026 AGM to Approve 2025 Accounts and Pay Report - TipRanks — TipRanks positive
- NEWS Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -36.3%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.94: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.59. Score 4.9/10, moderate confidence.
Analyst target: $6.26 (+26.8% upside). Prior stop was $4.59. Stop-loss: $4.59.
Quality below floor (3.4 < 4.0).
Alvotech trades at a P/E of N/A (forward 21.5). TrendMatrix value score: 6.6/10. Verdict: Sell.
13 analysts cover ALVO with a consensus score of 4.2/5. Average price target: $7.
What does Alvotech do?Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers...
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.